Trial Profile
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms EXPEDITION-5
- Sponsors AbbVie
- 13 Nov 2018 Results assessing the efficacy and safety of Glecaprevir/Pibrentasvir in patients with HCV genotype GT 1-6 infection and severe renal impairment using data from EXPEDITION-4 and EXPEDITION-5 studies (n=205), presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Jun 2018 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Preliminary results presented at the Digestive Disease Week 2018